Video

Dr. Sam on the Importance of Performing Geriatric Assessments During the COVID-19 Pandemic

Author(s):

Christine Sam, MD

In Partnership With:

Christine Sam, MD, discusses the importance of ​performing geriatric assessments during the coronavirus disease 2019 pandemic​.

Christine Sam, MD, hematologist and oncologist, assistant member, Department of Individualized Cancer Management/Senior Adult Oncology Program, Moffitt Cancer Center, discusses the importance of ​performing geriatric assessments during the coronavirus disease 2019 (COVID-19) pandemic​.

​Ensuring geriatric assessments are done can be challeng​ing in ​the clinic​al setting, says Sam. ​As such, having resources ​available to conduct this testing quickly and efficiently is of critical importance.

Common techniques include ​utilizing the CRASH (Chemotherapy Risk Assessment Scale for High-Age Patients) score, which stratifies patients into 4 risk categories for severe toxicity, as well as the CARG (Cancer Aging Research Group) score, both of which can be conducted online. 

Additionally, several ​physical assessments, such as the Timed Up and Go test, have been extremely beneficial ​in assessing older patients, especially during the COVID-19 pandemic, Sam concludes.

Related Videos
Grzegorz S. Nowakowski, MD
John Seymour, MBBS, FRACP, PhD
Sagar Lonial, MD, FACP
Sandip P. Patel, MD
Bradley McGregor, MD, director, clinical research, Lank Center for Genitourinary Oncology, Marra Lochiatto Investigator, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Moshe Ornstein, MD, MA, medical oncologist, Department of Hematology and Medical Oncology, Cleveland Clinic
Reid Merryman, MD
Partow Kebriaei, MD
John K. Lee, MD, PhD
Jean L. Koff, MD, MS
Related Content
Roger Li, MD, Moffitt Cancer Center
August 2nd 2024

Bladder-Sparing Treatment Post–Pembrolizumab Progression Is Effective in BCG-Unresponsive NMIBC

Andrew Kuykendall, MD
October 16th 2023

FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia

Kedar Kirtane, MD
July 18th 2024

Autologous TIL Therapy Plus Pembrolizumab Under Exploration in PD-L1–Resistant Advanced HNSCC

Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS
March 6th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

Bruna Pellini, MD, of Moffitt Cancer Center and Research Institute
May 16th 2024

Pellini Discusses Immunotherapies and Current Limitations of ctDNA in Perioperative NSCLC

Rami Komrokji, MD, vice chair, the Malignant Hematology Department, head, the Leukemia and Myelodysplastic Syndromes Section, Moffitt Cancer Center
February 28th 2024

NCCN Lists Ropeginterferon Alfa-2B As Preferred First-Line Cytoreductive Therapy for Polycythemia Vera